Diffuse Plaque

Background

Diffuse plaque refers to a widespread form of atherosclerosis, a condition characterized by the accumulation of lipids, inflammatory cells, and fibrous tissue within the arterial walls. Unlike localized, discrete lesions, diffuse plaque is more spread out and can affect major arteries throughout the body. This process, often referred to as subclinical atherosclerosis (SCA), can develop over decades before manifesting as clinically apparent cardiovascular diseases.^[1] It is a common finding in young and middle-aged individuals, highlighting its pervasive nature. ^[1]

Biological Basis

The biological basis of diffuse plaque involves a complex interplay of genetic predispositions and environmental factors that drive the atherosclerotic process. A key component is dyslipidemia, where elevated levels of certain lipoproteins, such as low-density lipoprotein (LDL) cholesterol and triglycerides, contribute significantly to plaque formation and an increased risk of coronary artery disease.^[2] Genome-wide association studies (GWAS) have identified numerous genetic loci that influence lipid concentrations, underscoring the genetic contribution to these metabolic imbalances. ^[2]For instance, specific alleles associated with increased LDL cholesterol concentrations are more frequently observed in individuals diagnosed with coronary artery disease.^[2]Additionally, chronic low-grade inflammation, often indicated by elevated C-reactive protein (CRP) levels, plays a critical role in the initiation and progression of atherogenesis.^[3] Advanced high-resolution imaging techniques are utilized to detect and quantify these early atherosclerotic changes within various arterial beds. ^[1]

Clinical Relevance

The presence of diffuse plaque and subclinical atherosclerosis carries significant clinical relevance as it is a strong predictor of future cardiovascular events, including myocardial infarction and stroke, which are leading causes of mortality globally.^[1]Research, including GWAS for SCA, is instrumental in identifying novel genetic variants that underlie atherosclerosis in specific or multiple arterial territories.^[1]Understanding the genetic architecture of lipid levels, for example, enables the assessment of an individual’s polygenic risk for dyslipidemia and associated cardiovascular conditions.^[4]Early detection of diffuse plaque and the stratification of risk based on genetic markers and imaging findings can guide preventive strategies and facilitate timely medical interventions, potentially altering disease trajectories.

Social Importance

From a societal perspective, diffuse plaque and its progression to clinical cardiovascular disease impose a substantial public health burden. Cardiovascular diseases are a major cause of death and disability, resulting in considerable healthcare expenditures and diminished quality of life.^[1]Ongoing research into the genetic underpinnings of atherosclerosis, including diffuse plaque, is crucial for deepening our understanding of disease mechanisms. This knowledge can pave the way for developing innovative diagnostic tools, more effective therapeutic targets, and personalized medicine approaches. By identifying individuals at a higher genetic risk, public health initiatives can be optimized to promote healthier lifestyles and encourage early medical interventions, thereby reducing the overall incidence and societal impact of cardiovascular disease.

Limitations

Methodological and Statistical Constraints

The studies often rely on moderate cohort sizes, which can limit the statistical power to detect genetic effects of modest magnitude, thereby increasing the risk of false negative findings where true associations might be overlooked. ^[5]For instance, power to detect associations with single nucleotide polymorphisms (SNPs) explaining less than 4% of total phenotypic variation may be limited, suggesting that variants with smaller contributions might remain undetected.^[6] Furthermore, distinguishing true genetic associations from false positives is a fundamental challenge in genome-wide association studies (GWAS) due to the extensive multiple testing involved. ^[5] The absence of external replication makes it difficult to synthesize findings with high confidence, as many previously reported phenotype-genotype associations fail to replicate, often due to initial false positives, cohort differences, or insufficient power in replication studies. ^[5]

The use of genotyping platforms with partial coverage, such as 100K SNP arrays, means that not all genetic variations are captured, potentially leading to missed associations for diffuse plaque as some genes might not be adequately represented.^[1] While imputation methods are employed to infer untyped SNPs, they are subject to error, with reported allele imputation error rates ranging between 1.46% and 2.14% in some studies, which could influence the accuracy of observed associations. ^[2] Additionally, population stratification, if not adequately addressed, can lead to spurious associations; however, several studies employed methods like genomic control or principal component analysis to minimize this risk. ^[7] The reliance on sex-pooled analyses also means that potential sex-specific genetic effects on phenotypes might remain undetected. ^[8]

Generalizability and Phenotype Assessment Limitations

A significant limitation is the demographic composition of the study cohorts, which are often largely white individuals of European descent, primarily middle-aged to elderly. ^[5]This demographic narrowness restricts the generalizability of findings concerning diffuse plaque to younger populations or individuals of other ethnic or racial backgrounds, as the occurrence and distribution of subclinical atherosclerosis, which includes diffuse plaque, can differ across diverse populations.^[5] Consequently, the identified genetic associations might not be universally applicable, necessitating replication in more diverse cohorts to confirm broader relevance.

The assessment of complex phenotypes, such as echocardiographic traits or subclinical atherosclerosis measures, can introduce limitations. Averaging measurements over extended periods, sometimes spanning two decades, might mask age-dependent gene effects and introduce misclassification due to evolving diagnostic equipment and methodologies over time.^[6]Moreover, current imaging modalities for subclinical atherosclerosis primarily focus on fixed anatomical components like calcific plaque or intimal-media thickness, rather than dynamic or metabolically active aspects of the disease.^[1]This narrow focus might not fully capture the complex biological underpinnings of diffuse plaque and its progression, potentially overlooking crucial aspects of the phenotype.

Unaccounted Factors and Remaining Knowledge Gaps

The studies generally do not undertake investigations into gene-environment interactions, which could significantly modulate the influence of genetic variants on phenotypes related to diffuse plaque.^[6] Environmental factors, such as dietary salt intake, have been shown to modify the associations of certain genes with traits, indicating that a purely genetic analysis may overlook crucial contextual influences. ^[6]The absence of such analyses means that potential confounders are not fully explored, leaving a gap in understanding the full etiology and risk factors for diffuse plaque.

While genome-wide association studies identify promising SNP associations and generate hypotheses, they do not inherently provide a complete biological understanding of diffuse plaque.^[5] The ultimate validation of these findings requires further functional models and replication in independent cohorts to confirm their true positive nature and biological relevance. ^[5]The complexity of traits like diffuse plaque suggests that a substantial portion of heritability may remain unexplained by individual common variants, pointing to the need for more comprehensive approaches to unravel the intricate genetic and environmental architecture underlying the trait.^[6]

Variants

Genetic variations play a crucial role in influencing an individual’s susceptibility to various health outcomes, including those related to diffuse plaque formation, a complex process involving lipid accumulation, inflammation, and cellular dysfunction. Among these, variants in theAPOEgene are particularly well-studied for their significant impact on lipid metabolism and neurodegenerative processes. The single nucleotide polymorphism (SNP)rs429358 , along with rs7412 (not in the given list, but key to APOE alleles), defines the common epsilon (e2, e3, e4) alleles of APOE, which dictate the protein’s isoform and its efficiency in transporting lipids. Variations within theAPOE-APOC1-APOC4-APOC2 gene cluster are strongly associated with altered levels of LDL cholesterol, a primary component of diffuse plaques, and have been linked to an increase in LDL cholesterol concentrations. ^[2] Furthermore, the APOEgene region on chromosome 19 has been implicated in the regulation of C-reactive protein (CRP), an inflammatory marker, suggesting a broader role in systemic inflammation that can contribute to plaque development.^[9]

Beyond lipid metabolism, other genes contribute to the intricate pathways underlying diffuse plaque. The genePPARGC1A (Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha) encodes a master transcriptional coactivator that regulates mitochondrial biogenesis, oxidative phosphorylation, and adaptive thermogenesis, playing a central role in energy metabolism within cells. ^[9] A variant like rs7437482 in PPARGC1A could potentially alter the gene’s expression or function, thereby impacting cellular energy production and stress responses, which are critical for maintaining cellular health and preventing the accumulation of misfolded proteins and lipids characteristic of diffuse plaques. ^[10] Such disruptions in metabolic efficiency can exacerbate cellular damage and contribute to the formation and persistence of diffuse plaques.

Long intergenic non-coding RNAs (lncRNAs) and their associated genes also emerge as significant players in complex biological processes. The variant rs62194957 is located near BMP2 and LINC01428. BMP2(Bone Morphogenetic Protein 2) is a growth factor involved in bone and cartilage development, but also plays roles in cellular differentiation and vascular calcification, processes that can indirectly influence plaque formation in various tissues.^[5] LINC01428, as an lncRNA, is likely involved in regulating gene expression, and a variant in this region could modulate the activity of nearby genes, including BMP2, or other pathways related to inflammation and tissue remodeling relevant to plaque pathology. ^[10] Similarly, rs585925 in LINC03004suggests a regulatory role for this lncRNA in cellular processes, where its alteration could affect gene networks involved in cellular stress, lipid handling, or immune responses, all of which are pertinent to the development of diffuse plaque.

Further extending the regulatory landscape, variants such as rs10850658 (near LINC02457 and LINC00173), rs73651385 (near LINC01239 and SUMO2P2), rs601419 (near CYCSP27 and LIPT2), rs10147155 (near NPAS3 and EGLN3), and rs2804986 (near TTC39B and RPL7P33) highlight the potential impact of lncRNAs and their neighboring genes. These lncRNAs, including LINC02457, LINC00173, LINC01239, CYCSP27, and NPAS3, are involved in various epigenetic and transcriptional regulatory mechanisms, influencing cell fate, metabolic pathways, and stress responses. ^[11] For instance, SUMO2P2 is a pseudogene related to SUMOylation, a post-translational modification crucial for protein stability and function, while LIPT2 is involved in lipoic acid metabolism, essential for mitochondrial enzymes. ^[10] EGLN3 plays a role in hypoxia response, and TTC39Bis associated with lipid metabolism. Alterations caused by these variants could impact cellular resilience, metabolic efficiency, and protein homeostasis, thereby contributing to the cellular environment conducive to diffuse plaque formation.

Key Variants

RS ID	Gene	Related Traits
rs429358	APOE	cerebral amyloid deposition measurement Lewy body dementia, Lewy body dementia measurement high density lipoprotein cholesterol measurement platelet count neuroimaging measurement
rs62194957	BMP2 - LINC01428	diffuse plaque measurement
rs7437482	PPARGC1A	diffuse plaque measurement
rs10850658	LINC02457 - LINC00173	diffuse plaque measurement
rs73651385	LINC01239 - SUMO2P2	diffuse plaque measurement
rs2804986	TTC39B - RPL7P33	diffuse plaque measurement
rs585925	LINC03004	diffuse plaque measurement
rs601419	CYCSP27 - LIPT2	diffuse plaque measurement chordin-like protein 2 measurement
rs10147155	NPAS3 - EGLN3	diffuse plaque measurement

Classification, Definition, and Terminology

Defining Subclinical Atherosclerosis and Calcified Lesions

Subclinical atherosclerosis (SCA) represents the presence of arterial disease before the manifestation of overt clinical symptoms, serving as an important intermediate phenotype in the pathway from standard cardiovascular risk factors to clinical cardiovascular disease (CVD).^[1] This condition is notably common in young and middle-aged individuals, highlighting its significance for early detection and risk stratification. ^[1]The ability to detect and quantify SCA in major arteries, such as the carotid and coronary arteries, is crucial for assessing an individual’s predisposition to future cardiovascular events, including stroke and heart failure .

A key manifestation within the spectrum of subclinical atherosclerosis is the calcified lesion, which can be found in the coronary arteries (Coronary Artery Calcification, CAC) and the aorta (Abdominal Aortic Calcification, AAC). These lesions are precisely defined in multidetector computed tomography (MDCT) scans as an area comprising at least three connected pixels with a CT attenuation exceeding 130 Hounsfield Units, based on 3D connectivity criteria.^[1]The presence and extent of such calcifications are recognized as fundamental components of the atherosclerotic process and are considered significant precursors of overt cardiovascular disease .

Classification and Measurement of Atherosclerotic Burden

The classification and measurement of atherosclerotic burden rely on several non-invasive, high-resolution imaging modalities and physiological assessments. These include the ankle-brachial index (ABI) for detecting peripheral arterial atherosclerosis, B-mode ultrasound for quantifying internal and common carotid intimal medial thickness (IMT), and multidetector computed tomography (MDCT) for assessing coronary artery calcium (CAC) and abdominal aortic calcium (AAC) deposits.^[1]Each of these measures provides a distinct and quantifiable indicator of subclinical atherosclerosis, with previous research indicating that these measures exhibit incomplete correlations across different arterial territories.^[1]

The quantification of calcified lesions, such as CAC and AAC, involves a specific scoring methodology where the area of a calcified lesion is multiplied by a weighted CT attenuation score. ^[1] This weighting is dependent on the maximal Hounsfield Units observed within the lesion, allowing for a standardized assessment of calcification severity. This algorithm represents a modification of the original Agatston Score, adapted for MDCT scan protocols, and has demonstrated excellent intra- and inter-reader reproducibility for CAC measurements, affirming its reliability in both clinical diagnostics and research endeavors. ^[1]

Terminology and Related Concepts in Atherosclerosis

The nomenclature associated with arterial plaque and its precursors encompasses several key terms essential for a comprehensive understanding of cardiovascular health. “Subclinical atherosclerosis” (SCA) serves as a broad conceptual framework, referring to various forms of arterial disease that are present without manifesting overt clinical symptoms, thereby representing an early pathological stage.^[1] More specific diagnostic terms for quantifiable lesions include “coronary artery calcium” (CAC) and “abdominal aortic calcium” (AAC), which precisely denote calcified deposits detectable through MDCT imaging. ^[1]

Further related concepts are crucial for characterizing the atherosclerotic process. “Intimal medial thickness” (IMT) of the carotid artery, measured by B-mode ultrasound, is recognized as a significant marker for atherosclerosis and an independent risk factor for myocardial infarction and stroke.^[12]Additionally, the “ankle-brachial index” (ABI) provides another valuable measure, specifically indicating the presence of peripheral arterial disease.^[1]Collectively, these terms and their associated measurement approaches describe the diverse manifestations of the atherosclerotic process, which is fundamentally linked to endothelial dysfunction as an early precursor to overt cardiovascular disease .

Causes of Diffuse Plaque

Diffuse plaque, a hallmark of atherosclerosis, results from a complex interplay of genetic predispositions, environmental exposures, developmental factors, and the presence of various comorbidities. Understanding these multifaceted influences is crucial for comprehending its etiology and progression.

Genetic Predisposition and Polygenic Risk

Genetic factors play a significant role in an individual’s susceptibility to conditions that contribute to diffuse plaque formation, such as dyslipidemia and elevated uric acid levels. Genome-wide association studies (GWAS) have identified numerous single nucleotide polymorphisms (SNPs) associated with variations in lipid concentrations, including LDL cholesterol, HDL cholesterol, and triglycerides, which are critical components in plaque development.^[4] For instance, common variants at 30 distinct loci have been shown to contribute to polygenic dyslipidemia, where the cumulative effect of multiple genes influences an individual’s lipid profile. ^[4] Similarly, specific genetic variants such as rs16890979 in SLC2A9, rs2231142 in ABCG2, and rs1165205 in SLC17A3have been strongly associated with uric acid concentrations, a biomarker linked to cardiovascular risk.^[13]The presence of these inherited variants, and their cumulative impact, contributes to an individual’s overall genetic risk score for developing conditions conducive to diffuse plaque.

Environmental and Lifestyle Influences

Beyond genetics, various environmental and lifestyle factors profoundly influence the risk of diffuse plaque. While specific dietary components or exposures are not detailed, broader epidemiological studies acknowledge the impact of environmental factors on biomarker traits associated with cardiovascular health.^[13] For example, researchers often consider “epidemiologic variables” when analyzing genetic associations, recognizing that external factors can significantly modify how genetic predispositions manifest. ^[14] These influences collectively contribute to the metabolic landscape, affecting processes like inflammation and lipid metabolism that are central to plaque formation.

Interplay of Genes, Environment, and Developmental Factors

The development of diffuse plaque is not solely determined by individual genetic variants or environmental exposures, but rather by their intricate interactions over time. Gene-environment interactions highlight how genetic predispositions can be activated or modulated by specific environmental triggers. For instance, studies have investigated the interaction between identified genetic variants (e.g.,rs16890979 , rs2231142 , rs1165205 ) and various environmental factors in influencing uric acid levels, demonstrating that an individual’s genetic makeup can affect their response to external stimuli.^[13]Furthermore, developmental factors, including early life influences, contribute to the long-term risk. For example, epidemiological evidence links C-reactive protein (CRP) concentrations to “early diabetogenesis and atherogenesis,” suggesting that pathways initiating early in life can lay the groundwork for later plaque development.^[3]

Comorbidities and Age-Related Contributions

Several other factors, including existing health conditions and the natural aging process, significantly contribute to the risk and progression of diffuse plaque. Comorbidities such as dyslipidemia, often managed with lipid-lowering therapies, are direct contributors to plaque formation.^[2]The presence of conditions like coronary artery disease, itself a consequence of plaque, indicates advanced stages where diffuse plaque is likely extensive.^[2]Additionally, age is a prominent factor; studies frequently involve cohorts that are “largely middle-aged to elderly,” underscoring that the accumulation of genetic, environmental, and lifestyle impacts over decades leads to a higher prevalence of plaque in older populations.^[5]

Biological Background

Lipid Metabolism and Atherogenesis

Diffuse plaque, a manifestation of atherosclerosis, is fundamentally driven by dysregulation in lipid metabolism, particularly the accumulation of low-density lipoprotein (LDL) cholesterol within arterial walls. High concentrations of LDL cholesterol are directly associated with an increased risk of coronary artery disease (CAD), while higher levels of high-density lipoprotein (HDL) cholesterol are linked to a decreased risk.^[15]Specifically, a 1% reduction in LDL cholesterol can decrease the risk of coronary heart disease by approximately 1%, whereas a 1% increase in HDL cholesterol can reduce this risk by about 2%.^[15]

Key biomolecules and genetic factors play significant roles in these processes. Genetic variants in genes such as the LDL receptor (LDLR) and apolipoprotein B (APOB) (rare variants), and apolipoprotein E (APOE) (common variants), have been associated with elevated LDL cholesterol concentrations and an increased susceptibility to coronary heart disease.^[15]Furthermore, single nucleotide polymorphisms (SNPs) inHMGCR, a gene critical for cholesterol synthesis, have been shown to affect alternative splicing of exon 13, influencing LDL-cholesterol levels. ^[16] Other genes like PCSK9and those influencing lipoprotein(a) (Lp(a)) levels also contribute to the complex genetic architecture of lipid concentrations and cardiovascular disease risk^[4]. ^[17]

Inflammatory and Hemostatic Pathways in Plaque Development

Beyond lipid accumulation, inflammatory and hemostatic processes are critical in the initiation, progression, and potential rupture of diffuse plaque. C-reactive protein (CRP), a marker of systemic inflammation, has concentrations epidemiologically linked to early diabetogenesis and atherogenesis.^[3] Genetic loci related to metabolic-syndrome pathways, including LEPR, HNF1A, IL6R, and GCKR, are associated with plasma CRP levels, indicating a genetic predisposition to inflammatory states that can exacerbate plaque development. ^[3]

Hemostatic factors and blood properties also contribute significantly to the pathophysiology of diffuse plaque. Platelet aggregation, fibrinogen, Factor VII (FVII), Plasminogen activator inhibitor-1 (PAI1), and von Willebrand factor (vWF) are crucial hemostatic factors that show genetic variation and are associated with cardiovascular disease risk^[18]. ^[19]Hemorheological disturbances, which involve alterations in blood viscosity and flow properties, are observed in patients with chronic cerebrovascular diseases and are recognized as factors in cerebral ischemia^[20]. ^[21] PDGF C(platelet-derived growth factor C), a selective alpha platelet-derived growth factor receptor agonist, is highly expressed in platelet alpha granules and vascular smooth muscle, suggesting its role in vascular remodeling and plaque progression.^[22]

Genetic Contributions to Atherosclerosis

The development of diffuse plaque and atherosclerosis has a substantial genetic component, influencing various intermediate phenotypes and overall disease risk. Family studies indicate that approximately half of the variation in individual lipid profiles is genetically determined.^[15]This genetic influence extends to a wide array of traits, with specific genetic variants contributing significantly to individual differences in lipid concentrations and, consequently, to the risk of coronary artery disease.^[15]

Genome-wide association studies (GWAS) have been instrumental in identifying numerous genetic variants, or SNPs, that are associated with subclinical atherosclerosis (SCA) phenotypes. These phenotypes include carotid intima-media thickness (IMT) and the presence of calcific plaque, which are measurable markers of early atherosclerotic disease.^[1]Such genetic investigations also pinpoint loci related to metabolic-syndrome pathways and hemostatic factors, highlighting the complex interplay of multiple genetic elements in predisposing individuals to atherosclerosis^[3]. ^[18] The impact of genetic variations can be at the molecular level, such as SNPs in HMGCR affecting the alternative splicing of exon 13, which in turn influences LDL-cholesterol levels. ^[16]

Tissue-Level Manifestations and Systemic Impact

Diffuse plaque, as part of the broader atherosclerotic process, manifests as structural changes at the tissue level within arterial walls, leading to significant systemic consequences. Atherosclerosis, characterized by the cumulative deposition of LDL cholesterol, is the primary underlying pathology for major cardiovascular events such as coronary artery disease (CAD) and stroke.^[15]Subclinical atherosclerosis phenotypes, including increased carotid artery intima-media thickness (IMT) and the presence of calcific plaque, are crucial indicators of disease progression and serve as independent risk factors for myocardial infarction and stroke in older adults^[1]. ^[12]

Beyond localized arterial changes, atherosclerosis influences and is influenced by broader organ-level biology. Left ventricular (LV) chamber size, wall thickness (LV remodeling), and mass (LVM) are fundamental in the pathogenesis of high blood pressure and clinical cardiovascular disease, including stroke and heart failure.^[6]Endothelial dysfunction, assessed through brachial artery flow-mediated dilation (FMD), is recognized as a fundamental component and a precursor of overt cardiovascular disease.^[6]These echocardiographic, endothelial, and exercise-related traits function as important intermediate phenotypes that bridge standard risk factors to the development of overt cardiovascular disease.^[6]

Pathways and Mechanisms

Lipid and Lipoprotein Homeostasis

The intricate balance of lipid and lipoprotein metabolism is central to the development of atherosclerotic plaque. The mevalonate pathway, responsible for cholesterol biosynthesis, is critically regulated by the enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR). ^[16] Genetic variants in HMGCRcan influence low-density lipoprotein (LDL) cholesterol levels, partly by affecting the alternative splicing of exon 13, thereby modulating enzyme activity.^[16] This pathway’s overall flux is under the control of transcription factors such as sterol regulatory element-binding protein 2 (SREBP-2), which regulates genes involved in cholesterol synthesis. ^[23]

Beyond synthesis, the processing and transport of lipoproteins are equally vital. Genes within the APOA cluster (APOA1, APOA4, APOA5, APOC3) and APOEare fundamental to the assembly, remodeling, and catabolism of lipoproteins, directly impacting circulating levels of high-density lipoprotein (HDL) and LDL.^[24]Furthermore, lipoprotein lipase (LPL) plays a crucial role in the hydrolysis of triglycerides within chylomicrons and very-low-density lipoproteins. ^[24] Proprotein convertase subtilisin/kexin type 9 (PCSK9) is another key regulator, influencing LDL-cholesterol levels, and its causal alleles are strongly associated with cardiovascular disease risk, establishing it as a significant therapeutic target.^[4] Variations in ANGPTL3 and ANGPTL4 also modulate lipid metabolism, with specific ANGPTL4 variants shown to reduce triglycerides and increase HDL. ^[2] Dysregulation across these interconnected pathways leads to dyslipidemia, a primary driver of plaque formation.

Fatty Acid Metabolism and Signaling

The synthesis and modification of fatty acids, particularly polyunsaturated fatty acids (PUFAs), are crucial metabolic processes impacting cellular membrane composition and signaling. The FADS gene cluster, encompassing FADS1 and FADS2, encodes fatty acid desaturases that catalyze key steps in the biosynthesis of PUFAs from precursor fatty acids. ^[25]Genetic variants, including single nucleotide polymorphisms (SNPs) and haplotypes, within this cluster are significantly associated with the fatty acid composition of phospholipids and the overall levels of PUFAs in human serum.^[25]

These desaturases are critical for maintaining the proper balance of various fatty acid species. For instance, certain genetic polymorphisms that lead to reduced desaturase activity can result in higher concentrations of longer-chain fatty acids (substrates) and lower concentrations of shorter-chain fatty acids (products), indicative of altered enzymatic turnover. ^[25]Fatty acids are also dynamically linked to energy metabolism, as they are bound to carnitine for transport into mitochondria, where they undergo beta-oxidation . This infiltration of immune cells is a foundational step in the development of atherosclerotic lesions. Polymorphisms withinCCL2have been associated with both serum MCP-1 levels and an increased risk of myocardial infarction, underscoring its relevance in cardiovascular disease pathogenesis.^[26]

Beyond inflammation, the regulation of blood coagulation and platelet function is paramount for vascular integrity and preventing thrombotic events associated with plaque rupture. Hemostatic factors and the propensity for platelet aggregation are recognized as critical contributors to the pathogenesis of coronary artery disease and acute coronary syndromes.^[8]Genetic variations in several thrombosis-related genes have been shown to influence plasma levels of hemostatic proteins and modulate the overall risk for cardiovascular disease.^[19] Furthermore, proteins such as Pleckstrin, which associates with plasma membranes and induces membrane projections in a phosphorylation-dependent manner, suggest roles in cellular remodeling and signaling within the vascular environment, potentially influencing processes like platelet activation or endothelial cell responses. ^[27]

Molecular Regulation of Gene Expression and Protein Function

The precise control of gene expression and protein activity is fundamental to all cellular processes, including those contributing to plaque formation. Transcriptional regulation, often mediated by specific transcription factors, dictates the cellular machinery available for metabolic and signaling pathways. For example, the transcription factor SREBP-2 is a key regulator of genes involved in cholesterol biosynthesis, controlling the expression levels of enzymes like HMGCR. ^[23] This hierarchical regulation ensures that the cell can adapt its metabolic output in response to internal and external cues.

Beyond transcriptional control, post-translational modifications provide another critical layer of regulation, rapidly altering protein function without requiring new protein synthesis. Protein phosphorylation, as demonstrated by its requirement for Pleckstrin’s association with membranes and induction of membrane projections, is essential for modulating protein activity and cellular responses. ^[27] Furthermore, alternative pre-mRNA splicing is a significant mechanism that can generate multiple protein isoforms from a single gene, each with potentially distinct functions. Common genetic variants in HMGCR, for instance, have been shown to affect the alternative splicing of exon 13, consequently impacting LDL-cholesterol levels. ^[16]This highlights how genetic variation can subtly yet profoundly influence protein function through modifications in mRNA processing, contributing to the complexity of disease mechanisms.

Systems-Level Integration and Disease Pathogenesis

The development of plaque is not attributable to isolated pathways but rather emerges from the complex, interconnected web of metabolic, signaling, and regulatory networks within the cardiovascular system. Dyslipidemia, influenced by genetic variants in lipid-processing genes likeHMGCR, FADS, APOA, and PCSK9, directly impacts the inflammatory state of the vasculature, which in turn can exacerbate hemostatic dysregulation. ^[25]These pathways engage in extensive crosstalk, where the output of one pathway can significantly modulate the activity of others, leading to a dynamic and often self-perpetuating disease process. The body often attempts compensatory mechanisms in response to initial pathway dysregulation, but chronic or overwhelming imbalances can lead to emergent properties characteristic of atherosclerotic plaque, such as its growth, calcification, or vulnerability to rupture.^[25]

Understanding these systems-level interactions is crucial for identifying effective therapeutic strategies. The identification of specific pathway dysregulations, such as the role of PCSK9 in LDL-cholesterol regulation, has led to the development of highly effective targeted therapies. ^[4]Approaches like genome-wide association network analysis (GWANA) facilitate the identification of biologically enriched pathways among genes associated with disease, providing a framework for deciphering the hierarchical regulation and network interactions that underpin plaque pathogenesis.^[24]This integrated view allows for a more comprehensive understanding of disease mechanisms and the potential for multi-target interventions.

Clinical Relevance of Diffuse Plaque

The clinical relevance of diffuse plaque, representing widespread atherosclerotic burden, is multifaceted, encompassing its utility in risk assessment, prognosis, and informing preventive strategies for cardiovascular disease. Understanding its implications is crucial for patient care, from early detection to managing associated comorbidities.

Assessment and Prognostic Value

Measures of subclinical atherosclerosis (SCA) across various arterial territories serve as critical indicators for evaluating an individual’s cardiovascular risk. Carotid artery intima-media thickness (IMT), coronary artery calcium (CAC), and abdominal aortic calcium (AAC) are heritable phenotypes associated with an increased incidence of cardiovascular disease, even before overt symptoms manifest.^[1]For instance, carotid artery IMT is recognized as a significant risk factor for myocardial infarction and stroke, particularly in older adults.^[12]

Beyond diagnostic utility, these markers carry substantial prognostic value. Abdominal aortic calcific deposits are important predictors of vascular morbidity and mortality^[28]while the coronary artery calcium score is widely utilized to predict future coronary heart disease events.^[29]Furthermore, the ankle-brachial index (ABI) demonstrates sensitivity and specificity in predicting future cardiovascular outcomes.^[30]Clinical assessment, such as categorizing carotid artery stenosis severity (e.g., >80% stenosis, 15-79% stenosis, or <15% stenosis), directly reflects the extent of diffuse plaque and guides risk stratification for conditions like carotid artery disease.^[17]

Genetic Risk and Personalized Prevention

Genetic risk profiles offer a promising avenue for enhanced risk stratification and personalized medicine approaches in cardiovascular disease prevention. Studies indicate that genetic risk scores can predict dyslipidemia, improving the discriminative accuracy for conditions like hypercholesterolemia beyond traditional factors such as age, sex, and body mass index.^[24]The addition of genetic profiles to conventional clinical risk factors, including lipid values and age, also refines coronary heart disease (CHD) risk classification.^[24]

This improved predictive capability suggests that genetic information could be instrumental for the early detection and treatment of dyslipidemias and related cardiovascular risks, thereby enabling more targeted preventive strategies.^[24]For example, a genetic risk score for total cholesterol was significantly associated with clinically defined hypercholesterolemia and improved the prediction of this condition, highlighting its utility in identifying high-risk groups.^[24]

Associated Conditions and Systemic Implications

Diffuse plaque and its underlying risk factors are frequently associated with a range of comorbidities and systemic conditions, highlighting the interconnectedness of metabolic and inflammatory pathways in disease progression. Obesity, for instance, is correlated with lipid levels, which are direct contributors to atherosclerosis.^[24]Furthermore, C-reactive protein (CRP), a key inflammatory biomarker, has been epidemiologically linked to early diabetogenesis and atherogenesis.^[3] Genetic variants in genes such as HNF1A, IL6R, and GCKR have been found to associate with plasma CRP levels ^[9] with IL6R polymorphisms specifically impacting CRP expression and correlating with IL-6 levels, which in turn predict future vascular events and diabetes. ^[3]

The APOE locus is another significant genetic region, with polymorphisms known to associate with an increased risk of myocardial infarction and premature atherothrombosis. ^[3]These genetic insights underscore the complex interplay between lipid metabolism, inflammation, and other metabolic-syndrome pathways in the development and progression of widespread atherosclerosis and its related complications, including type 2 diabetes and various other traits.^[4]

References

[1] O’Donnell, C. J. et al. “Genome-wide association study for subclinical atherosclerosis in major arterial territories in the NHLBI’s Framingham Heart Study.”BMC Medical Genetics, vol. 8, suppl. 1, 2007, p. S4. PubMed, PMID: 17903303.

[2] Willer, C. J. et al. “Newly identified loci that influence lipid concentrations and risk of coronary artery disease.”Nature Genetics, vol. 40, no. 2, 2008, pp. 161–69. PubMed, PMID: 18193043.

[3] Ridker, P. M. et al. “Loci related to metabolic-syndrome pathways including LEPR, HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women’s Genome Health Study.”American Journal of Human Genetics, vol. 82, no. 1, 2008, pp. 122–32. PubMed, PMID: 18439548.

[4] Kathiresan, S, et al. “Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans.”Nat Genet, vol. 40, no. 2, 2008, pp. 189-97.

[5] Benjamin, E. J., et al. “Genome-wide association with select biomarker traits in the Framingham Heart Study.” BMC Med Genet, vol. 8, suppl. 1, 2007, p. S9.

[6] Vasan, Ramachandran S. “Genome-wide association of echocardiographic dimensions, brachial artery endothelial function and treadmill exercise responses in the Framingham Heart Study.”BMC Medical Genetics, vol. 8, 2007, p. 73.

[7] Pare, Guillaume, et al. “Novel association of ABO histo-blood group antigen with soluble ICAM-1: results of a genome-wide association study of 6,578 women.” PLoS Genetics, vol. 4, no. 7, 2008, e1000118.

[8] Yang, Q., et al. “Genome-wide association and linkage analyses of hemostatic factors and hematological phenotypes in the Framingham Heart Study.”BMC Medical Genetics, vol. 8, 2007, p. 61.

[9] Reiner, A. P., et al. “Polymorphisms of the HNF1Agene encoding hepatocyte nuclear factor-1 alpha are associated with C-reactive protein.”American Journal of Human Genetics, vol. 82, no. 5, 2008, pp. 1193-1201.

[10] Kathiresan, S. et al. “Common variants at 30 loci contribute to polygenic dyslipidemia.” Nature Genetics, vol. 41, no. 1, 2009, pp. 56–65. PubMed, PMID: 19060906.

[11] Wallace, C., et al. “Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia.”Am J Hum Genet, vol. 82, no. 1, 2008, pp. 139-49.

[12] O’Leary, D. H., et al. “Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group.”New England Journal of Medicine, vol. 340, 1999, pp. 14-22.

[13] Dehghan, Abbas, et al. “Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study.”Lancet, vol. 372, no. 9654, 2008, pp. 1823-31.

[14] Sabatti, Chiara, et al. “Genome-wide association analysis of metabolic traits in a birth cohort from a founder population.”Nature Genetics, vol. 41, no. 1, 2009, pp. 35-42.

[15] Willer, CJ, et al. “Newly identified loci that influence lipid concentrations and risk of coronary artery disease.”Nat Genet, vol. 40, no. 2, 2007, pp. 161-69.

[16] Burkhardt, R, et al. “Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon13.” Arterioscler Thromb Vasc Biol, vol. 28, no. 11, 2008, pp. 2078-84.

[17] Ober, C, et al. “Genome-wide association study of plasma lipoprotein(a) levels identifies multiple genes on chromosome 6q.”J Lipid Res, vol. 50, no. 5, 2009, pp. 889-98.

[18] Yang, Q, et al. “Genome-wide association and linkage analyses of hemostatic factors and hematological phenotypes in the Framingham Heart Study.”BMC Med Genet, vol. 7, no. 1, 2006, p. S1.

[19] Kathiresan, S, et al. “Common Genetic Variation in Five Thrombosis Genes and Relations to Plasma Hemostatic Protein Level and Cardiovascular Disease Risk.”Arterioscler Thromb Vasc Biol, vol. 26, no. 6, 2006, pp. 1405-12.

[20] Szapary, L, et al. “Hemorheological disturbances in patients with chronic cerebrovascular diseases.”Clin Hemorheol Microcirc, vol. 31, no. 1, 2004, pp. 1-9.

[21] Fisher, M, and HJ Meiselman. “Hemorheological factors in cerebral ischemia.”Stroke, vol. 22, no. 9, 1991, pp. 1164-69.

[22] Fang, L, et al. “PDGF C Is A Selective {alpha} Platelet-Derived Growth Factor Receptor Agonist That Is Highly Expressed in Platelet {alpha} Granules and Vascular Smooth Muscle.”Arterioscler Thromb Vasc Biol, vol. 24, no. 4, 2004, pp. 787-92.

[23] Murphy, C., et al. “Regulation by SREBP-2 defines a potential link between isoprenoid and adenosylcobalamin metabolism.” Biochemical and Biophysical Research Communications, vol. 355, no. 2, 2007, pp. 359-64.

[24] Aulchenko, Y. S., et al. “Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts.”Nature Genetics, vol. 40, no. 11, 2008, pp. 1297-305.

[25] Gieger, C., et al. “Genetics Meets Metabolomics: A Genome-Wide Association Study of Metabolite Profiles in Human Serum.”PLoS Genetics, vol. 4, no. 11, 2008, e1000282.

[26] McDermott, D. H., et al. “CCL2 polymorphisms are associated with serum monocyte chemoattractant protein-1 levels and myocardial infarction in the Framingham Heart Study.”Circulation, vol. 112, no. 8, 2005, pp. 1113-20.

[27] Ma, A. D., et al. “Pleckstrin associates with plasma membranes and induces the formation of membrane projections: requirements for phosphorylation and the NH2-terminal PH domain.” The Journal of Cell Biology, vol. 136, no. 5, 1997, pp. 1071-79.

[28] Wilson, P. W., et al. “Abdominal aortic calcific deposits are an important predictor of vascular morbidity and mortality.”Circulation, vol. 103, 2001, pp. 1529-1534.

[29] Pletcher, M. J., et al. “Using the coronary artery calcium score to predict coronary heart disease events: a systematic review and meta-analysis.”Archives of Internal Medicine, vol. 164, 2004, pp. 1285-1292.

[30] Doobay, A. V., and S. S. Anand. “Sensitivity and specificity of the ankle-brachial index to predict future cardiovascular outcomes: a systematic review.”Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, 2005, pp. 1463-1469.